April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Ocular Complications Of NewColorIris(TM) Cosmetic Iris Implants
Author Affiliations & Notes
  • Ambika S. Hoguet
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • David Ritterband
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • Richard Koplin
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • Elaine Wu
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • John Aljian
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • Tal Raviv
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • John Seedor
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • Footnotes
    Commercial Relationships  Ambika S. Hoguet, None; David Ritterband, None; Richard Koplin, None; Elaine Wu, None; John Aljian, None; Tal Raviv, None; John Seedor, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1962. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ambika S. Hoguet, David Ritterband, Richard Koplin, Elaine Wu, John Aljian, Tal Raviv, John Seedor; Ocular Complications Of NewColorIris(TM) Cosmetic Iris Implants. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1962.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To identify the presenting symptoms and subsequent management of a series of patients presenting with NewColorIris(TM) cosmetic iris implants.

 
Methods:
 

The medical records of 14 eyes of 7 patients presenting with NewColorIris(TM) cosmetic iris implants treated at the New York Eye and Ear Infirmary were reviewed. Data collected included patient demographics, visual acuity (VA), intraocular pressure (IOP), endothelial cell count (ECC), and slit lamp examination findings at presentation. Medical and surgical interventions were also tabulated.

 
Results:
 

14 eyes in 7 patients (ages 22-60; 71% Male, 29% Female) were identified. 64% (9/14) of eyes presented with decreased VA (<20/30); 50% (7/14) with elevated IOP; 36% (6/14) with corneal edema; and 36% (6/14) with iritis. Average initial IOP was 26 (range 16-52) and the average ECC was 1055 (range 266-1841). All eyes were eventually treated with explantation of the iris prosthesis (range 4-33 months after implant placement), although 2 patients (4 eyes) refused immediate explantation (explants were subsequently performed 4-15 months after presentation). The minimum follow-up after explantation for all eyes was 2 months (range 2-28 months). Intraoperative complications included suprachoroidal hemorrhage during explantation (1/14). Post operative complications included corneal edema (11/14), cataract (9/14), and increased IOP (6/14). Secondary surgeries included descemet's stripping automated endothelial keratoplasty (5/14), cataract extraction/intraocular lens placement (4/14), trabeculectomy (3/14), tube placement (3/14), goniosynechiolysis (2/14), and penetrating keratoplasty (1/14). On most recent followup, 12/14 showed improvement in IOP, 8/14 showed improved or stable VA, 6/14 had worse VA (including 3/4 who deferred immediate explantation).

 
Conclusions:
 

NewColorIris(TM) implants can cause serious complications including uveitis, glaucoma, corneal edema, and decreased visual acuity. Explantation may help stabilize symptoms but in most cases ocular morbidity is high requiring additional surgical intervention to control IOP and corneal decompensation.

 
Keywords: anterior segment • intraocular pressure • iris 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×